University of Southern California

California Institute of Technology

Cancer Biologics, Inc.

Techniclone, Inc.

Clive R Taylor

Alan L Epstein

Emil Paskalev Kartalov

Axel Scherer

Ashraf Imam

John K Liu

Rainer Hintsche

Lawrence A Wade

Rene Seitz

Darryl Shibata

Robert D MacPhee

Shan Rong Shi

S Ashraf Imam

Described herein are methods for quantitative target detection in a sample through use of microbeads and related devices and systems.

Methods for quantitative target detection and related devices and systems

Provided herein are devices and methods for the micro-isolation of biological cellular material. A micro-isolation apparatus described can comprise a photomask that protects regions of interest against DNA-destroying illumination. The micro-isolation apparatus can further comprise photosensitive material defining access wells following illumination and subsequent developing of the photosensitive material. The micro-isolation apparatus can further comprise a chambered microfluidic device comprising channels providing access to wells defined in photosensitive material. The micro-isolation apparatus can comprise a chambered microfluidic device without access wells defined in photosensitive material where valves control the flow of gases or liquids through the channels of the microfluidic device. Also included are methods for selectively isolating cellular material using the apparatuses described herein, as are methods for biochemical analysis of individual regions of interest of cellular material using the devices described herein. Further included are methods of making masking arrays useful for the methods described herein.

Methods and devices for micro-isolation, extraction, and/or analysis of microscale components

Methods for identifying Quantifiable Internal Reference Standards (QIRS) for immunohistochemistry (IHC). Also disclosed are methods for using QIRS to quantify test antigens in IHC.

Quantifiable internal reference standards for immunohistochemistry and uses thereof

Multi-valve autoregulatory microfluidic devices and methods are described. The described devices and methods offer improved performance and new means of tuning autoregulatory effects in microfluidic devices.

Multi-valve microfluidic devices and methods

Described herein is a method for detection of a target in a sample and related devices and systems.

An immunochemical and molecular biologic endpoint reporter system in which reaction products, coupled to electrochemically active molecules susceptible to redox recycling or coupled to enzymes capable of proportional generation of said electrochemically active molecules, are detected and/or quantitated using amperiometry in conjunction with a silicon microchip possessing a closely spaced interdigitated array of nobel metal electrodes.

Electrochemical reporter system for detecting analytical immunoassay and molecular biology procedures

Disclosed are methods for identifying the presence of a tumor in a mammal, comprising the steps of obtaining an antibody against cell ghosts, wherein the antibody is specific to an intracellular antigen not present on the cell surface of normal or neoplastic cells, and wherein the antibody is labeled with a label capable of being imaged; administering the antibody to the mammal, thereby permitting the antibody to bind preferentially to necrotic tissue; and imaging the binding of the antibody to the necrotic tissue, wherein a localized concentration of said antibody is indicative of the presence of a tumor. The antibodies used in these methods are preferably monoclonal antibodies, are also preferably specific for one or more nuclear proteins, and are also preferably labeled with one or more radionuclides. Also disclosed are antibodies for use with the foregoing methods.

Detection of necrotic malignant tissue and associated therapy

Disclosed is a method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of the mammal but not to external cellular components, wherein the monoclonal antibody is labeled; contacting the labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo, and determining the effectiveness of the therapy by measuring the binding of the labeled antibody to the internal cellular component. The internal cellular component is preferably insoluble intracellular antigen, and the label is preferably a radionuclide, a radiopaque material, or a magnetic resonance-enhancing material. Also disclosed is a method whereby the antibody to insoluble intracellular antigen is conjugated to an antineoplastic agent, so that upon administration of the antibody-antineoplastic agent conjugate, antineoplastic agent may be delivered to the tumor. Also disclosed are antibodies for use with the foregoing methods.

A cell-surface glycoprotein, termed luminal epithelial antigen, having a molecular weight of 135 Kd and which is present in normal mammary epithelial cell lines but not in malignant epithelial cell lines. A monoclonal antibody directed against said luminal epithelial antigen. Use of the monoclonal antibody in a diagnostic assay for the early identification of patients with high risk of developing breast cancer and in a prognostic assay for the prediction of recurrence of breast cancer in patients.

Luminal epithelial antigen

The invention relates to a new antigen termed BLA-36 specifically expressed on the surface of Hodgkin's cells, Reed-Sternberg cells and B lymphocytes, and to a new monoclonal antibody (anti-BLA-36) specific thereto. The antigen is characterized by the following properties:

Antibody to antigen specifically expressed on the surface of B cells and

The invention relates to a new antigen termed BLA-35 specifically expressed on the surface of Hodgkin's cells, Reed-Sternberg cells and B lymphocytes, and to a new monoclonal antibody (anti-BLA-36) specific thereto. The antigen is characterized by the following properties:

Antigen specifically expressed on the surface of B cells and Hodgkin's

Disclosed is a method for enhancing the effects of therapy that kills malignant cells in vivo comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of a mammal but not to external cellular components, wherein the monoclonal antibody is attached to an antineoplastic agent; initiating therapy in a mammal to kill malignant cells in vivo, thereby causing some of the malignant cells to become necrotic; and administering the antibodies to the mammal. The antibodies bind to the necrotic malignant cells thereby delivering antineoplastic agent to surrounding cells. Also disclosed is a method of de novo therapy comprising administration of antibody-antineoplastic agent conjugate such that antineoplastic agent is delivered to the tumor. Also disclosed are antibodies for use with the foregoing methods and for use with diagnositc methods.

Growing community of inventors

Malibu, CA, United States of America

Clive R Taylor